JGC
PCRX icon

J. Goldman & Co’s Pacira BioSciences PCRX Stock Holding History

J. Goldman & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-245,000
Closed -$9.2M – 413
2017
Q3 		$9.2M Buy
+245,000
New +$9.86M 0.46% 62

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's PCRX Position: Q2 2026 in Review

J. Goldman & Co reduced its Pacira BioSciences (PCRX) stake by 77% in Q2 2026, selling an estimated $1.79M and leaving 22,078 shares worth $560K. The position accounts for 0.01% of the portfolio, ranked #540.

J. Goldman & Co first reported a position in PCRX in Q3 2017 and has held it in 12 quarters since. The position peaked at $21.3M in Q1 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • J. Goldman & Co held 22,078 shares of Pacira BioSciences worth $560K as of Q2 2026.
  • J. Goldman & Co sold 75,694 Pacira BioSciences shares in Q2 2026, an estimated $1.79M.
  • Pacira BioSciences made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #540 holding.
  • J. Goldman & Co first reported a position in Pacira BioSciences in Q3 2017 and has held it in 12 quarters since.
  • J. Goldman & Co's Pacira BioSciences position peaked at $21.3M in Q1 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.